Financière de Tubize – Annual Report 2022

3 years ago

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: eric.nys@financiere-tubize.be Annual Report 2022 Regulated information25 February 2023…

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

3 years ago

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,…

Regional Health Properties, Inc. Regains Compliance with NYSE American Continued Listing Standards

3 years ago

ATLANTA, GA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “we,” “us” or “our”) (NYSE American:…

IRADIMED CORPORATION Issues Urgent Medical Device Correction

3 years ago

Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter SetWINTER SPRINGS, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE)…

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

3 years ago

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on…

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

3 years ago

Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology…

SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering

3 years ago

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a…

SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit

3 years ago

DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical…

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin, 1 January – 31 December 2022 (unaudited)

3 years ago

BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin, 24 February 2023 at 3.00 p.m. BBS advances towards the CE marking of…

Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis

3 years ago

Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ,…